Emerging kinase inhibitors of the treatment of gastric cancer

Bibliography

• Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_ cancer.aspx [Last Accessed 28 December 2014]
   Google Scholar
• SEER Stat Fact Sheets:Stomach Cancer. Available from: http:/seer.cancer.gov/statfacts/html/stomach.html [Last Accessed 28 December 2014]
   Google Scholar
• Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010(3):CD004064
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD):an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31–9
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–35
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9
   PubMed Web of Science ®Google Scholar
• Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy:a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009;27:3786-93
   PubMed Web of Science ®Google Scholar
• Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag 2008;4:999-1007
   PubMedGoogle Scholar
• European Society of Medical Oncology (ESMO) guidelines for gastric cancer. Available from: http://www.esmo.org/Guidelines-Practice/Clinical-Practice-Guidelines/GastrointestinalCancers/Gastric-Cancer [Last Accessed 28 December 2014]
   Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6
   PubMed Web of Science ®Google Scholar
• Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005;1:2005.0010
   PubMed Web of Science ®Google Scholar
• Matsubara J, Yamada Y, Hirashima Y, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008;14:3022-9
   PubMed Web of Science ®Google Scholar
• Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8(8):492-503
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31:1458-68
   PubMed Web of Science ®Google Scholar
• Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008;15:69-79
   PubMed Web of Science ®Google Scholar
• Zhen Y, Guanghui L, Xiefu Z. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther 2014;21:491-7
   PubMed Web of Science ®Google Scholar
• Ema A, Waraya M, Yamashita K, et al. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. Cancer Med 2015;4:90-100
   PubMedGoogle Scholar
• Roskoski RJr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11
   PubMed Web of Science ®Google Scholar
• Fassan M, Mastracci L, Grillo F, et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012;61:769-76
   PubMed Web of Science ®Google Scholar
• Sukawa Y, Yamamoto H, Nosho K, et al. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion 2014;89:12-17
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer:results from a validation study. Histopathology 2008;52:797-805
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma:association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
   PubMed Web of Science ®Google Scholar
• Cidon EU, Centeno RG, Lagarto EG, et al. HER-2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain. 2011;2011:391564
   Google Scholar
• Fornaro L, Lucchesi M, Caparello C, et al. Anti-HER agents in gastric cancer:From bench to bedside. Nat. Rev. Gastroenterol. Hepatol 2011;8:369-83
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Lenz HJ, et al. S0413:A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J. Clin. Oncol 2007;25:4621
   Web of Science ®Google Scholar
• Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy:Phase II efficacy and biomarker analyses [abstract 43]. Gastrointestinal Cancers Symposium (ASCO); 2008
   Google Scholar
• Galsky MD, von Hoff DD, Neubauer M, et al. Target-specific, histology independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012;30:695-701
   PubMed Web of Science ®Google Scholar
• Moehler MH, Schad A, Mauer ME, et al. Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status:A randomized placebo controlled phase II (EORTC 40071). J Clin Oncol 2015;33:abstract 80, 2015 Gastrointestinal Cancers Symposium
   Google Scholar
• Bang YJ. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population:Tytan study. J Clin Oncol 2013;31:abstract 11
   Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC):The TRIO-013/LOGiC Trial. J Clin Oncol 2013;31:abstract LBA4001
   Google Scholar
• Janjigian YY, Ku GY, Ilson DH, et al. A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer. J Clin Oncol 2015;33:abstract 59
   Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127. J Clin Oncol 2006;24:4922-7
   PubMed Web of Science ®Google Scholar
• Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-16
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentration of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000;153:7-12
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;7:858-63
   Web of Science ®Google Scholar
• . Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients:Correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002;236:37-42
   PubMed Web of Science ®Google Scholar
• Liu L, Ma XL, Xiao ZL, et al. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer Prev 2012;13:3089-97
   PubMed Web of Science ®Google Scholar
• Hirashima Y, Yamada Y, Matsubara J, et al. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci 2009;100:310-15
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76
   PubMed Web of Science ®Google Scholar
• Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cis as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2012;30:306-15
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O’Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cis in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma:ECOG 5203. J Clin Oncol 2010;28:2947-51
   PubMed Web of Science ®Google Scholar
• Martin-Richard M, Gallego R, Pericay C, et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs 2013;31:1573-9
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29:1449-58
   PubMed Web of Science ®Google Scholar
• Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011;47:1511-20
   PubMed Web of Science ®Google Scholar
• Yi JH, Lee L, Lee J, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer 2012;106:1469-74
   PubMed Web of Science ®Google Scholar
• Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012;69:439-46
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized, placebo-controlled, parallel-arm, phase II trial. Clin Oncol 2013;31:3219-25
   Web of Science ®Google Scholar
• Qin S. Phase III study of apatinib in advanced gastric cancer:A randomized, double-blind, placebo-controlled trial [abstract 4003]. J Clin Oncol 2014;32:5s
   PubMed Web of Science ®Google Scholar
• Cidon EU, Ellis SG, Inam Y, et al. Molecular Targeted Agents for Gastric Cancer:A Step Forward Towards Personalized Therapy. Cancers 2013;5:64-91
   PubMedGoogle Scholar
• Ko AH, Tabernero J, De Paredes MG, et al. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ). J Clin Oncol 2010;28:e14575
   Web of Science ®Google Scholar
• Kim ST, Jang HL, Lee SJ, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther 2014;13:2527-36
   PubMed Web of Science ®Google Scholar
• FLO +/- pazopanib as first-line treatment in advanced gastric cancer (PaFLO). Available from: http://clinicaltrials.gov/ct2/show/NCT01503372 [Last Accessed 28 December 2014]
   Google Scholar
• A study of pazopanib with CAPEOX in AGC patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01130805 [Last Accessed 28 December 2014]
   Google Scholar
• Study Of axitinib in combination with cisplatin and capecitabine in patients with advanced gastric cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00842244?term=kinase+inhibitors+gastric+cancer&rank=18 [Last Accessed 18 January 2015]
   Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Sjoquist KM, Tsobanis E, et al. INTEGRATE:A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. J Clin Oncol 2015;33(suppl 3); abstr 9
   PubMed Web of Science ®Google Scholar
• Hassan B, Akcakanat A, Holder AM, et al. Targeting the PI3-kinase/Akt/mtor signaling pathway. Surg Oncol Clin N Am 2013;22(10):1016
   Google Scholar
• Meric-Bernstam F, Akcakanat A, Chen HQ, et al. PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clin Cancer Res 2012;18:1777-89
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-8
   PubMed Web of Science ®Google Scholar
• Lim T, Lee J, Lee DJ, et al. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 2011;68:255-62
   PubMed Web of Science ®Google Scholar
• Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28:1904-10
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Yeh K, Bang Y, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC):GRANITE-1. J Clin Oncol (Meeting Abstracts) 2012;30(suppl 4); abstr LBA3
   Google Scholar
• Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol 2005;37:1572-7
   PubMed Web of Science ®Google Scholar
• Barr AR, Gergely F. Aurora-A:the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96
   PubMed Web of Science ®Google Scholar
• Huck JJ, Zhang M, McDonald A, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010;8:373-84
   PubMed Web of Science ®Google Scholar
• Görgün G, Calabrese E, Hideshima T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115:5202-13
   PubMed Web of Science ®Google Scholar
• Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors – rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
   PubMed Web of Science ®Google Scholar
• Rugge M, Fassan M, Zaninotto G, et al. Aurora kinase A in Barrett’s carcinogenesis. Hum Pathol 2010;41:1380-6
   PubMed Web of Science ®Google Scholar
• Sehdev V, Katsha A, Arras J, et al. HDM2 regulation by AURKA promotes cell survival in gastric cancer. Clin Cancer Res 2014;20:76-86
   PubMed Web of Science ®Google Scholar
• Katsha A, Soutto M, Sehdev V, et al. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 2013;145:1312-22
   PubMed Web of Science ®Google Scholar
• Wang J, Yang S, Zhang H, et al. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011;26:23-32
   PubMed Web of Science ®Google Scholar
• Özdemiri M, Öznur M, Çiftçi E, et al. Detection of kinase amplifications in gastric adenocarcinomas. Turk J Med Sci 2014;44:461-70
   PubMed Web of Science ®Google Scholar
• Dar AA, Belkhiri A, El-Rifai W. The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene 2009;28:866-75
   PubMed Web of Science ®Google Scholar
• Kamada K, Yamada Y, Hirao T, et al. Amplification/overexpression of Aurora-A in human gastric carcinoma:potential role in differentiated typegastric carcinogenesis. Oncol Rep 2004;12(3):593-9
   PubMed Web of Science ®Google Scholar
• Sehdev V, Peng D, Soutto M, et al. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 2012;11:763-74
   PubMed Web of Science ®Google Scholar
• Cammareri P, Scopelliti A, Todaro M, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010;70
   Google Scholar
• Yuan CX, Zhou ZW, Yang YX, et al. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther 2015;9:487-508
   PubMed Web of Science ®Google Scholar
• Alisertib and combination chemotherapy in treating patients with gastrointestinal tumors. available from https://clinicaltrials.gov/ct2/show/NCT02319018?term=alisertib&rank=11 [Last Accessed 28 January 2015]
   Google Scholar
• Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7
   PubMed Web of Science ®Google Scholar
• Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104:4106-11
   PubMed Web of Science ®Google Scholar
• Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8
   PubMed Web of Science ®Google Scholar
• Schellens JH, Boss D, Witteveen PO, et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. Journal of Clinical Oncology 2006;24
   Google Scholar
• Gizatullin F, Yao Y, Kung V, et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-77
   PubMed Web of Science ®Google Scholar
• Soncini C, Carpinelli P, Gianellini L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006;12:4080-9
   PubMed Web of Science ®Google Scholar
• Emanuel S, Rugg CA, Gruninger RH, et al. The in vitro and in vivo effects of JNJ-7706621:a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65:9038-46
   PubMed Web of Science ®Google Scholar
• Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27(1):85-94
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25
   PubMed Web of Science ®Google Scholar
• Gholamin S, Fiuji H, Maftouh M, et al. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers:rationale and progress. Curr Drug Targets 2014;15:1302-11
   PubMed Web of Science ®Google Scholar
• Noguchi E, Saito N, Kobayashi M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancerprogression. Mol Med Rep 2015;10.3892/mmr.2015.3205
   Web of Science ®Google Scholar
• Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227-32
   PubMed Web of Science ®Google Scholar
• Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011;29:4789-95
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4
   PubMed Web of Science ®Google Scholar
• Shah MA, Wainberg ZA, Catenacci DVT, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013;8:e54014
   PubMed Web of Science ®Google Scholar
• Kang YK, Muro K, Ryu MH, et al. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs 2014;32:355-61
   PubMed Web of Science ®Google Scholar
• Kwak EL, LoRusso P, Hamid O, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. 2015 Gastrointestinal Cancers Symposium. J Clin Oncol 2015;33:abstract 1
   Google Scholar
• Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-10
   PubMed Web of Science ®Google Scholar
• Phase 2 study assessing efficacy and safety of crizotinib in patients harboring an alteration on ALK, MET or ROS1 (AcSé). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02034981?term=crizotinib+gastric+cancer&rank=1 [Last Accessed 28 January 2015]
   Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling:from development to cancer. Nat Rev Cancer 2010;10:116-29
   PubMed Web of Science ®Google Scholar
• Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8
   PubMed Web of Science ®Google Scholar
• Murase H, Inokuchi M, Takagi Y, et al. Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. Mol Clin Oncol 2014;2:509-17
   PubMedGoogle Scholar
• Xie L, Su X, Zhang L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013;19:2572-83
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012;106:727-32
   PubMed Web of Science ®Google Scholar
• Katoh M, Hattori Y, Sasaki H, et al. K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase. Proc Natl Acad Sci USA 1992;89:2960-4
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Yashiro M, Nishii T, et al. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signalling. Int J Cancer 2014;134:1785-95
   PubMed Web of Science ®Google Scholar
• Zhao WM, Wang L, Park H, et al. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res 2010;16:5750-8
   PubMed Web of Science ®Google Scholar
• Takeda M, Arao T, Yokote H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007;13:3051-7
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yashiro M, Matsuoka T, et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006;131:1530-41
   PubMed Web of Science ®Google Scholar
• Dovitinib for gastric cancer with FGFR2 amplification. Available from: https://clinicaltrials.gov/ct2/show/NCT01719549 [Last Accessed 28 January 2015]
   Google Scholar
• Dovitinib plus docetaxel in gastric cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01921673 [Last Accessed 28 January 2015]
   Google Scholar
• Efficacy and safety of AZD4547 versus paclitaxel in advanced gastric or gastro-oesophageal junction cancer patients (SHINE). Available from: https://www.clinicaltrials.gov/ct2/show/NCT01457846?term=azd+4547+shine&rank=1 [Last Accessed 28 January 2015]
   Google Scholar
• Amanchy R, Zhong J, Hong R, et al. Identification of c-Src tyrosine kinase substrates in PDGF receptor signaling pathway. Mol Oncol 2009;3:439-50
   PubMed Web of Science ®Google Scholar
• Amanchy R, Iwahori A, Molina H, et al. Identification of c-Src tyrosine kinase substrates using mass spectrometry and peptide microarrays. Journal of Proteome Research 2008;7:3900-10
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609
   PubMed Web of Science ®Google Scholar
• Humar B, Fukuzawa R, Blair V, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007;67:2480-9
   PubMed Web of Science ®Google Scholar
• Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther 2013;12:16-26
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Au HJ, McWhirter E, et al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma:a trial of the PMH phase II consortium. Invest New Drugs 2012;30:1158-63
   PubMed Web of Science ®Google Scholar
• Morgan DO. The cell cycle: principles of control. 1st edition. New Science Press; London: 2007
   Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 1995;374:131-3
   PubMed Web of Science ®Google Scholar
• Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-40
   PubMed Web of Science ®Google Scholar
• Dickson MA. Molecular pathways:CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Farsi K, Maslak P, et al. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997;3:1467-72
   PubMed Web of Science ®Google Scholar
• Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Dickson MA, Feldman DR, et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009;15:7405-11
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. 2001;19:1985-92
   Google Scholar
• Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00991952?term=irinotecan+with+alvocidib&rank=1 [Last Accessed 28 January 2015]
   Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82
   PubMed Web of Science ®Google Scholar
• Shattuck DL, Miller JK, Carraway KL, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008;68:1471-7
   PubMed Web of Science ®Google Scholar
• Lee YY, Kim HP, Kang MJ, et al. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med 2013;45:e64
   PubMed Web of Science ®Google Scholar
• Corso S, Ghiso E, Cepero V, et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 2010;9:121
   PubMed Web of Science ®Google Scholar
• Garrett JT, Olivares MG, Rinehart C, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011;108:5021-6
   PubMedGoogle Scholar
• Bass AJ, Thorsson V, Shmulevich I, et al. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9
   PubMed Web of Science ®Google Scholar
• Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012;61:673-84
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Polite BN, Henderson L, et al. Toward personalized treatment for gastroesophageal adenocarcinoma (GEC):Strategies to address tumor heterogeneity—PANGEA. J Clin Oncol 2014;3
   PubMed Web of Science ®Google Scholar
• Ali SM, Sanford EM, Klempner SJ, et al. Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. The Oncologist 2015;2014-0378
   Google Scholar
• Chen CT, Kim H, Liska D, et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 2012;11:660-9
   PubMed Web of Science ®Google Scholar
• Catenacci DVT. Next-generation clinical trials:Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015;9(5):967-96
   PubMed Web of Science ®Google Scholar